Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Fennec Pharmaceuticals ( (TSE:FRX) ).
Fennec Pharmaceuticals reported record 2025 net PEDMARK sales of $44.6 million, up 50% year over year, with fourth-quarter sales rising 75%, driven by higher patient enrollments, improved conversion rates, and accelerating adoption at key accounts. The company strengthened its commercial footing by expanding its field team, advancing multiple investigator-initiated studies in adult and AYA cancer populations, and securing $42 million in oversubscribed equity offerings, underscoring confidence in PEDMARK’s potential to reshape the standard of care for cisplatin-treated patients and to support further growth and international validation, including positive trial results in Japan.
The most recent analyst rating on (TSE:FRX) stock is a Buy with a C$18.00 price target. To see the full list of analyst forecasts on Fennec Pharmaceuticals stock, see the TSE:FRX Stock Forecast page.
Spark’s Take on FRX Stock
According to Spark, TipRanks’ AI Analyst, FRX is a Neutral.
The score is primarily held back by mixed financial performance (TTM losses, renewed cash burn, and weak capitalization in the provided statements) and bearish technical signals (below key moving averages with negative MACD). Positive corporate events provide an offset through improved commercial momentum and clinical/financing progress, but not enough to outweigh the current financial and trend risks.
To see Spark’s full report on FRX stock, click here.
More about Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on oncology supportive care, with its lead product PEDMARK aimed at reducing cisplatin-induced hearing loss in pediatric, adolescent, and adult cancer patients. The company targets key cancer centers and adolescent and young adult populations, leveraging institution-led clinical studies and real-world data to expand PEDMARK’s use across tumor types and global markets, including Japan.
Average Trading Volume: 905
Technical Sentiment Signal: Sell
Current Market Cap: C$297M
Find detailed analytics on FRX stock on TipRanks’ Stock Analysis page.